Phase I/II Study of the Selective RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET gene abnormalities | NYU Langone Health

Go Back to All Clinical Trials

Phase I/II Study of the Selective RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET gene abnormalities

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Advanced Solid Tumors With Evidence Of Ret Gene Abnormalities.
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:

1) Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1. 2) Available RET-gene abnormalities determined on tissue biopsy or liquid biopsy. 3) Adequate hematopoietic function. 4) Adequate hepatic function.

You may not be eligible for this study if the following are true:

1) Lactating woman. 2) Investigational agents or anticancer therapy within 5 half-lives prior to the first dose of study drug. 3) Major surgery (excluding placement of vascular access) within 4 weeks prior to the first dose of study drug; patients planning to undergo major surgery during the course of study treatment should require sponsor approval.